Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Dopamine agonists Stories

2010-12-07 12:56:01

A drug prescribed for Parkinson's disease may also treat restless leg syndrome without the adverse side effects of current therapies, Medical College of Georgia researchers say. Rasagaline works by prolonging the effect of dopamine, a chemical that transmits signals between nerve cells in the brain. The cause of RLS is unknown, but research suggests a dopamine imbalance. Parkinson's is caused by a dopamine insufficiency. "The hope is that Rasagaline, because it prolongs the effect of existing...

2010-11-30 07:00:00

BURLINGTON, Mass., Nov. 30, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when comparing dopamine agonist use for Parkinson's disease, more frequent use of once-daily formulations of Requip (GlaxoSmithKline's Requip, Requip XL/LP/Modutab/RP/Prolib) and Mirapex (Boehringer Ingelheim's Mirapex/Sifrol/Mirapexin; Mirapex ER/Mirapexin ER/Sifrol Retard) occurs in France than in the remaining...

2010-10-21 13:06:25

Researchers at the University of Copenhagen have succeeded in creating a model of the way the brain releases dopamine, an important chemical involved in transmitting signals between nerve cells. The model, the product of an interdisciplinary collaboration, will be an important tool in helping scientists understand how we learn and how the brain perceives reward and punishment. It is hoped that the model can be used to understand drug addiction and in the treatment of schizophrenia. In the...

2010-10-06 07:45:00

NESS ZIONA, Israel, October 6, 2010 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical...

2010-10-04 22:58:35

A researcher from the Faculty of Medicine & Dentistry at the University of Alberta has discovered a mechanism underlying some forms of obesity and addictions which could lead to a treatment for both diseases. When a hungry animal finds food in the wild, it is a rewarding stimulus for the animal and is recognized by the brain by the release of the chemical messenger dopamine. Because narcotics such as cocaine, heroin and amphetamines, and even tasty and highly-caloric foods also cause the...

2010-09-30 11:00:00

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms. Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related...

2010-09-28 06:58:00

NESS ZIONA, Israel, September 28, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announce today that a platform presentation highlighting the company's new dermal patch for the treatment of Parkinson's disease, ND0611, was given yesterday at the 14th Congress of the European Federation of Neurological Societies in Geneva, Switzerland. A poster presentation will be given at the 2nd World Parkinson's Congress in Glasgow, Scotland. (Sep 28th - Oct 1st, 2010). The presentation described results of...

2010-09-09 07:00:00

BURLINGTON, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, although increased uptake of currently-available therapies will drive modest $400 million growth in the Parkinson's disease drug market through 2019, generic erosion of key agents will constrain overall market growth in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010...

2010-08-16 09:12:00

HARRISBURG, Pa., Aug. 16 /PRNewswire-USNewswire/ -- On the street it's known as meth, speed, ice, chalk, crank, fire, glass or crystal. Methamphetamine is a highly addictive drug that wreaks havoc on the entire body, including the user's oral health. Approximately 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users. As the effects of methamphetamine use are devastating, the Pennsylvania Dental Association (PDA) wants to educate the public about...

2010-07-28 07:00:00

BRUSSELS, July 28 /PRNewswire/ -- UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours. "In this study...